For Radiodermatitis, a Natural Product Compares Well to the Standard of Care

TON - September 2016, Vol 9, No 5 - Supportive Care
Caroline Helwick

San Antonio, TX—For the treatment of radiodermatitis, a skin product containing calendula (a type of marigold) resulted in faster healing than Aquaphor plus aloe vera gel, according to interim results of a comparative study presented as a poster at the Oncology Nursing Society 41st Annual Congress.

Almost all patients with breast cancer treated with radiation therapy develop some degree of radiodermatitis, and various topical agents can be applied for relief. Results from recent studies comparing calendula to other topical agents have been contradictory, according to Susan Getz, BSN, RN, OCN, Maine Medical Center, Portland, who presented the study.

Ms Getz and colleagues designed an open-label, randomized controlled trial comparing the effectiveness of an ointment containing calendula (the intervention) to Aquaphor plus aloe vera (standard care) in preventing and treating radiodermatitis. They obtained the calendula product from a woman in the community who makes skin care products containing natural substances.

The study enrolled 110 patients, mostly white, with a fair skin type, no smoking history, and a mean age of 51 years. Women were instructed to apply the calendula ointment 4 times a day, or the Aquaphor plus aloe vera 3 times a day.

Outcomes Fairly Similar

The researchers observed no significant differences between product treatment groups for development of skin irritation during each week of radiation, defined as a Radiation Therapy Oncology Group score of ≥2. However, significantly fewer patients using calendula experienced skin irritation 2 weeks after radiation therapy (P = .025), and patients appeared to heal faster, Ms Getz said.

“We were hoping calendula could reduce this irritation. It didn’t significantly do that, but we did see the calendula group heal faster, which we were not expecting,” she stated, explaining that “healing” means they returned to near-baseline appearance.

“Improved time to healing postradiation is an important clinical outcome for these women,” she added.

Skin irritation was assessed week by week, with the following incidence observed for calendula compared with the control arm:

  • 0% versus 2% in week 2
  • 4% versus 8% in week 3
  • 19% versus 23% in week 4
  • 47% versus 41% in week 5
  • 70% versus 50% in week 6
  • 67% versus 83% in week 7
  • 5% versus 24% in week 8.

There were no significant differences between the skin product groups for quality of life or self-reported pain at each week of the study.

Ms Getz now gives her patients a choice between calendula and Aquaphor plus aloe vera gel, but she noted that calendula costs more, and that patients must pay for it.

Source: Getz S, et al. Open label randomized clinical study comparing calendula versus Aquaphor and aloe vera gel in women with breast cancer undergoing radiotherapy. Poster 187.

Related Items
Managing Bone Metastases Through a Multidisciplinary Approach
Meg Barbor, MPH
JHOP Web Exclusives published on December 11, 2018 in Supportive Care
Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting
Meg Barbor, MPH
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Supportive Care
A Taxing Consequence: Taxane Acute Pain Syndrome
Mark L. Zangardi, PharmD, BCOP
JHOP - June 2017 Vol 7, No 2 published on May 30, 2017 in Supportive Care, Symptom Management Overview
Helping Adolescents and Young Adults Confront Mortality
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Supportive Care
The Emerging Conversation About Physician-Assisted Death
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Supportive Care
EGFR Inhibitor–Associated Papulopustular Rash
Donald C. Moore, PharmD, BCPS, BCOP
JHOP - March 2017 Vol 7, No 1 published on March 13, 2017 in Supportive Care
Barriers to Initiating Oral Oncolytics by Specialty Pharmacy or Payers Can Affect Patient Outcomes
Leslie Wyatt
In the News: Oncology - February 2017 published on February 15, 2017 in Supportive Care
NCCN Campaign May Prevent Fatal Medication Errors by Targeting Vincristine Preparation
Caroline Helwick
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Best Practices
Toxicities Associated with Targeted Therapy and Immunotherapy Underreported in Published Studies
Alice Goodman
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Supportive Care
High Rates of Vancomycin-Resistant Enterococci Bacteremia Observed in Patients Receiving Allogeneic Hematopoietic Stem-Cell Transplant
Caroline Helwick
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Supportive Care
Last modified: September 14, 2016